

Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C2000A2E6ED6EN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: C2000A2E6ED6EN

Abstracts

The 7 major coccidioidomycosis markets reached a value of US\$ 132.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 209.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The coccidioidomycosis market has been comprehensively analyzed in IMARC's new report titled "Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coccidioidomycosis, also known as valley fever, refers to a fungal infection that arises due to the inhalation of spores from the fungi *Coccidioides posadasii* or *Coccidioides immitis*. The indications of this condition can vary widely, ranging from mild flu-like symptoms to serious and potentially life-threatening complications. The ailment usually manifests as fever, cough, fatigue, headache, and muscle aches. In some cases, the disorder can progress to a more severe form, leading to pneumonia, skin rashes, joint pain, and, rarely, dissemination to several other organs, like the brain and bones. The diagnosis of coccidioidomycosis typically involves a combination of clinical evaluation, imaging studies, physical examination, and laboratory tests. The healthcare provider may also conduct blood workups to detect antibodies against the fungi or use imaging techniques, such as CT scans or chest X-rays, to identify characteristic lung lesions. In severe cases or when dissemination is suspected, a biopsy may be necessary for confirmation.

The rising prevalence of inhaling airborne fungal spores due to disturbances in the soil caused by factors like dust storms and construction activities is primarily driving the coccidioidomycosis market. In addition to this, the escalating incidence of somatic mutations in the GNAQ gene, leading to overgrowth of the fungus in certain regions of the body, particularly the respiratory system, is a crucial factor fueling the market

growth. Furthermore, the increasing utilization of effective antifungal medications, such as azoles, polyenes, echinocandins, etc., to manage the condition and prevent complications is creating a positive outlook for the market. Apart from this, the widespread adoption of preventive measures, including wearing masks and avoiding high-risk areas, has also contributed to the market's expansion. Additionally, the rising popularity of early diagnosis through serological tests and chest X-rays, enabling prompt treatment and reducing disease progression, is acting as another significant growth-inducing factor. Moreover, the emerging trend of adopting combination therapy, involving a few different types of antifungal agents in severe cases, is further augmenting the market growth. Additionally, the growing research and development efforts towards launching a therapeutic vaccine aimed at providing long-term immunity and prevention against the disease are expected to drive the coccidioidomycosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the coccidioidomycosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for coccidioidomycosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coccidioidomycosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the coccidioidomycosis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the coccidioidomycosis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current coccidioidomycosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the coccidioidomycosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the coccidioidomycosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the coccidioidomycosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of coccidioidomycosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of coccidioidomycosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of coccidioidomycosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with coccidioidomycosis across the seven major markets?

What is the size of the coccidioidomycosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of coccidioidomycosis?

What will be the growth rate of patients across the seven major markets?

Coccidioidomycosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for coccidioidomycosis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coccidioidomycosis market?

What are the key regulatory events related to the coccidioidomycosis market?

What is the structure of clinical trial landscape by status related to the

coccidioidomycosis market?

What is the structure of clinical trial landscape by phase related to the coccidioidomycosis market?

What is the structure of clinical trial landscape by route of administration related to the coccidioidomycosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 COCCIDIOIDOMYCOSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 COCCIDIOIDOMYCOSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 COCCIDIOIDOMYCOSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 COCCIDIOIDOMYCOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 COCCIDIOIDOMYCOSIS - UNMET NEEDS

10 COCCIDIOIDOMYCOSIS - KEY ENDPOINTS OF TREATMENT

11 COCCIDIOIDOMYCOSIS - MARKETED PRODUCTS

- 11.1 List of Coccidioidomycosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 COCCIDIOIDOMYCOSIS - PIPELINE DRUGS

12.1 List of Coccidioidomycosis Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. COCCIDIOIDOMYCOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. COCCIDIOIDOMYCOSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 COCCIDIOIDOMYCOSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Coccidioidomycosis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Coccidioidomycosis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Coccidioidomycosis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Coccidioidomycosis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Coccidioidomycosis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Coccidioidomycosis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Coccidioidomycosis - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Coccidioidomycosis - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Coccidioidomycosis - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Coccidioidomycosis - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Coccidioidomycosis - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Coccidioidomycosis - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Coccidioidomycosis - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Coccidioidomycosis - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Coccidioidomycosis - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Coccidioidomycosis - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Coccidioidomycosis - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Coccidioidomycosis - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Coccidioidomycosis - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Coccidioidomycosis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Coccidioidomycosis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Coccidioidomycosis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Coccidioidomycosis - Access and Reimbursement Overview

16 COCCIDIOIDOMYCOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 COCCIDIOIDOMYCOSIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 COCCIDIOIDOMYCOSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C2000A2E6ED6EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2000A2E6ED6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

